JP2013519632A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519632A5
JP2013519632A5 JP2012552048A JP2012552048A JP2013519632A5 JP 2013519632 A5 JP2013519632 A5 JP 2013519632A5 JP 2012552048 A JP2012552048 A JP 2012552048A JP 2012552048 A JP2012552048 A JP 2012552048A JP 2013519632 A5 JP2013519632 A5 JP 2013519632A5
Authority
JP
Japan
Prior art keywords
zoledronic acid
molecular complex
water
lysine
api
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519632A (ja
JP5792748B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2010/043916 external-priority patent/WO2011014781A1/en
Priority claimed from PCT/US2010/043892 external-priority patent/WO2011014766A2/en
Application filed filed Critical
Priority claimed from PCT/US2011/023427 external-priority patent/WO2011097269A1/en
Publication of JP2013519632A publication Critical patent/JP2013519632A/ja
Publication of JP2013519632A5 publication Critical patent/JP2013519632A5/ja
Application granted granted Critical
Publication of JP5792748B2 publication Critical patent/JP5792748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552048A 2010-02-06 2011-02-02 結晶化法及びバイオアベイラビリティ Expired - Fee Related JP5792748B2 (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US30211010P 2010-02-06 2010-02-06
US61/302,110 2010-02-06
US31287910P 2010-03-11 2010-03-11
US61/312,879 2010-03-11
US31850310P 2010-03-29 2010-03-29
US61/318,503 2010-03-29
US33302810P 2010-05-10 2010-05-10
US33304110P 2010-05-10 2010-05-10
US61/333,028 2010-05-10
US61/333,041 2010-05-10
US35954410P 2010-06-29 2010-06-29
US61/359,544 2010-06-29
US12/847,568 2010-07-30
PCT/US2010/043916 WO2011014781A1 (en) 2009-07-31 2010-07-30 Novel oral forms of a phosphonic acid derivative
PCT/US2010/043892 WO2011014766A2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
USPCT/US2010/043892 2010-07-30
USPCT/US2010/043916 2010-07-30
US12/847,568 US8399023B2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
US37981410P 2010-09-03 2010-09-03
US61/379,814 2010-09-03
US45577810P 2010-10-26 2010-10-26
US61/455,778 2010-10-26
PCT/US2011/023427 WO2011097269A1 (en) 2010-02-06 2011-02-02 Crystallization method and bioavailability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015156109A Division JP6190429B2 (ja) 2010-02-06 2015-08-06 結晶化法及びバイオアベイラビリティ

Publications (3)

Publication Number Publication Date
JP2013519632A JP2013519632A (ja) 2013-05-30
JP2013519632A5 true JP2013519632A5 (OSRAM) 2014-03-27
JP5792748B2 JP5792748B2 (ja) 2015-10-14

Family

ID=44355747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012552048A Expired - Fee Related JP5792748B2 (ja) 2010-02-06 2011-02-02 結晶化法及びバイオアベイラビリティ
JP2015156109A Expired - Fee Related JP6190429B2 (ja) 2010-02-06 2015-08-06 結晶化法及びバイオアベイラビリティ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015156109A Expired - Fee Related JP6190429B2 (ja) 2010-02-06 2015-08-06 結晶化法及びバイオアベイラビリティ

Country Status (15)

Country Link
EP (1) EP2531200B1 (OSRAM)
JP (2) JP5792748B2 (OSRAM)
AU (2) AU2012216632B2 (OSRAM)
CA (1) CA2826548A1 (OSRAM)
CY (1) CY1119192T1 (OSRAM)
DK (1) DK2531200T3 (OSRAM)
ES (1) ES2638072T3 (OSRAM)
HR (1) HRP20171201T1 (OSRAM)
HU (1) HUE035744T2 (OSRAM)
IL (1) IL221306A0 (OSRAM)
LT (1) LT2531200T (OSRAM)
PL (1) PL2531200T3 (OSRAM)
PT (1) PT2531200T (OSRAM)
SI (1) SI2531200T1 (OSRAM)
WO (1) WO2011097269A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980868B2 (en) 2009-07-31 2015-03-17 Thar Pharmaceuticals, Inc. Oral forms of a phosphonic acid derivative
PL2459176T3 (pl) 2009-07-31 2018-02-28 Grünenthal GmbH Sposób krystalizacji i biodostępność
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
HRP20171201T1 (hr) * 2010-02-06 2017-10-06 Grünenthal GmbH Postupak kristalizacije i biodostupnost
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN102268023B (zh) * 2011-08-15 2013-04-17 南京丰融化学技术有限公司 头孢类衍生物cxd的晶型
SMT201800212T1 (it) * 2012-05-14 2018-07-17 Antecip Bioventures Ii Llc Composizione comprendenti acido zoledronico o composti correlati per alleviare dolore infiammatorio e condizioni associate
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10188617B2 (en) 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy
ES3042216T3 (en) 2013-03-15 2025-11-19 Xortx Therapeutics Inc Xanthine oxidase inhibitor formulations
JP6166471B2 (ja) * 2013-10-25 2017-07-19 アンテシップ バイオベンチャーズ トゥー エルエルシー ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
CN108601791A (zh) * 2015-09-18 2018-09-28 格兰泰有限公司 结晶方法和生物利用度
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR102723076B1 (ko) * 2016-12-15 2024-11-28 제이투에이치바이오텍 (주) 3성분 코크리스탈
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CA2454200A1 (en) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
EP1612212A1 (en) * 2003-07-03 2006-01-04 Teva Pharmaceutical Industries Ltd Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US20060068010A1 (en) 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PL2459176T3 (pl) * 2009-07-31 2018-02-28 Grünenthal GmbH Sposób krystalizacji i biodostępność
US8980868B2 (en) * 2009-07-31 2015-03-17 Thar Pharmaceuticals, Inc. Oral forms of a phosphonic acid derivative
HRP20171201T1 (hr) * 2010-02-06 2017-10-06 Grünenthal GmbH Postupak kristalizacije i biodostupnost
US9340565B2 (en) * 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN102070668B (zh) * 2010-12-23 2013-07-24 蚌埠丰原医药科技发展有限公司 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法

Similar Documents

Publication Publication Date Title
JP2013519632A5 (OSRAM)
JP2016006096A5 (OSRAM)
US8980868B2 (en) Oral forms of a phosphonic acid derivative
JP2010077141A5 (OSRAM)
HRP20171201T1 (hr) Postupak kristalizacije i biodostupnost
JP2013500995A5 (OSRAM)
SI2459176T1 (en) Crystallization process and bioavailability
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
JP2009102342A5 (OSRAM)
JP2020097577A5 (OSRAM)
JP2015536964A5 (OSRAM)
JP2017537899A5 (OSRAM)
JP2016534063A5 (OSRAM)
JP2011051993A5 (OSRAM)
JP2010090149A5 (OSRAM)
JP2012533565A5 (OSRAM)
JP2014505017A5 (OSRAM)
JP2017532316A5 (OSRAM)
JP2014530181A5 (OSRAM)
JP2011513377A5 (OSRAM)
JP2012504584A5 (OSRAM)
RU2013148627A (ru) Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии
JP2014509637A5 (OSRAM)
JP2008528617A5 (OSRAM)